University Of Texas Denali Therapeutics Inc. Transaction History

University Of Texas

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 29, 2024	BUY	$15.83 - $23.35 $481,675 - $710,493	30,428 New	30,428 $624,000
Q4 2023 Aug 29, 2024	BUY	$16.2 - $23.18 $492,933 - $705,321	30,428 New	30,428 $652,000
Q4 2023 Feb 28, 2024	BUY	$16.2 - $23.18 $492,933 - $705,321	30,428 New	30,428 $653,000
Q2 2023 Aug 04, 2023	BUY	$23.37 - $32.96 $853,308 - $1.2 Million	36,513 New	36,513 $1.08 Million
Q4 2021 Feb 15, 2022	SELL	$42.59 - $55.02 $1.79 Million - $2.31 Million	-41,918 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$48.48 - $78.23 $2.03 Million - $3.28 Million	41,918 New	41,918 $2.12 Million
Q2 2021 Aug 06, 2021	SELL	$50.3 - $78.44 $1.19 Million - $1.85 Million	-23,629 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$53.8 - $81.53 $1.27 Million - $1.93 Million	23,629 New	23,629 $1.35 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of University Of Texas, based on Form 13F filings with the SEC.

Stay updated on University Of Texas with notifications on news.